Literature DB >> 12540854

Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.

Ramanathan Natesh1, Sylva L U Schwager, Edward D Sturrock, K Ravi Acharya.   

Abstract

Angiotensin-converting enzyme (ACE) has a critical role in cardiovascular function by cleaving the carboxy terminal His-Leu dipeptide from angiotensin I to produce a potent vasopressor octapeptide, angiotensin II. Inhibitors of ACE are a first line of therapy for hypertension, heart failure, myocardial infarction and diabetic nephropathy. Notably, these inhibitors were developed without knowledge of the structure of human ACE, but were instead designed on the basis of an assumed mechanistic homology with carboxypeptidase A. Here we present the X-ray structure of human testicular ACE and its complex with one of the most widely used inhibitors, lisinopril (N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline; also known as Prinivil or Zestril), at 2.0 A resolution. Analysis of the three-dimensional structure of ACE shows that it bears little similarity to that of carboxypeptidase A, but instead resembles neurolysin and Pyrococcus furiosus carboxypeptidase--zinc metallopeptidases with no detectable sequence similarity to ACE. The structure provides an opportunity to design domain-selective ACE inhibitors that may exhibit new pharmacological profiles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540854     DOI: 10.1038/nature01370

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  152 in total

1.  Mass spectral fragmentation reactions of angiotensin-converting enzyme (ACE) inhibitors.

Authors:  David J Burinsky; Scott L Sides
Journal:  J Am Soc Mass Spectrom       Date:  2004-09       Impact factor: 3.109

2.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 3.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

4.  Metallopeptide-promoted inactivation of angiotensin-converting enzyme and endothelin-converting enzyme 1: Toward dual-action therapeutics.

Authors:  Nikhil H Gokhale; J A Cowan
Journal:  J Biol Inorg Chem       Date:  2006-07-28       Impact factor: 3.358

5.  Validated ligand mapping of ACE active site.

Authors:  Daniel J Kuster; Garland R Marshall
Journal:  J Comput Aided Mol Des       Date:  2005-11-24       Impact factor: 3.686

6.  A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.

Authors:  Amanda L McClerren; Stephanie Endsley; Jason L Bowman; Niels H Andersen; Ziqiang Guan; Johannes Rudolph; Christian R H Raetz
Journal:  Biochemistry       Date:  2005-12-20       Impact factor: 3.162

Review 7.  Novel molecular angiotensin converting enzyme and angiotensin receptor imaging techniques.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

Review 8.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

9.  Interpretable correlation descriptors for quantitative structure-activity relationships.

Authors:  Benson M Spowage; Craig L Bruce; Jonathan D Hirst
Journal:  J Cheminform       Date:  2009-12-24       Impact factor: 5.514

10.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.